NEWS

New Trial Alert: Alliance A062101 Relapsed or Refractory Multiple Myeloma

September 17, 2024

Alliance A062101: A phase I/II study of the safety, tolerability and efficacy of belantamab mafodotin (GSK2857916) in combination with iberdomide (CC-220)/dexamethasone versus belantamab mafodotin (GSK2857916)/dexamethasone in relapsed refractory multiple myeloma

Monique A. Hartley-Brown, MD, MMSc, of Dana-Farber Cancer Institute, leads Alliance A062101 – a phase I/II trial to test t


Alliance Presents Results From AMBASSADOR Trial for Patients with High-Risk Muscle -Invasive Bladder Cancer at ESMO 2024 and Published in New England Journal of Medicine

September 17, 2024

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder. Researchers found that postsurgical treatment with pembrolizumab (K


Alliance Presents Final Results From Phase III CABINET Trial Evaluating Cabozanitib in Advanced Neuroendocrine Tumors at ESMO 2024 and Published in New England Journal of Medicine

September 16, 2024

The Alliance for Clinical Trials in Oncology today announced final results will be presented at ESMO 2024 from CABINET (A021602), a phase III trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients


Older News